Sponsors (2)
The bill strengthens FDA oversight, reporting, inspections, and funding to improve the safety and quality of compounded drugs, but it increases compliance, reporting, and fee burdens that may limit access or raise costs—especially for patients needing slight drug modifications and for small compounding businesses.
Patients and hospitals: stronger safety and quality of compounded drugs through limits on routine replication of commercially available products, mandatory reporting/registration, increased inspections, and fee-funded oversight.
Prescribers and patients: clinicians retain authority to request individualized compounded therapies when they determine a significant medically necessary difference is required.
Regulators and manufacturers: clearer rules and standardized, Secretary-prescribed reporting/registration create better national visibility and regulatory clarity about which commercially available drugs cannot be routinely compounded and about compounding volumes.
Patients who need slightly modified versions of commercially available drugs: possible reduced access, delays, or higher costs if compounders hit the 20-per-month cap or if regulations narrowly prohibit common modifications.
Small independent compounding pharmacies and outsourcing facilities: increased compliance, inspection, reporting, and fee costs could reduce revenues or force closures, concentrating compounding services and raising prices or reducing local access.
Pharmacies and clinicians: added monthly reporting, registration, and inspection requirements create administrative burden and compliance costs—disproportionately affecting smaller or out-of-state compounders.
Based on analysis of 5 sections of legislative text.
Tightens limits and reporting on compounded copies of commercially available drugs, requires inspections and registration for high-volume outsourcing facilities, and lets HHS set compounder base fees.
Introduced February 5, 2026 by James E. Banks · Last progress February 5, 2026
Restricts and tracks compounding of products that are essentially copies of drugs sold on the U.S. market, requires reporting by compounders who ship many such products across state lines, subjects high-volume outsourcing facilities to initial and regular FDA inspections and registration, and gives the HHS Secretary discretion to set the base establishment fee for compounders instead of a fixed number. The changes aim to increase safety oversight of compounded drug products while creating new reporting, inspection, and fee-setting authorities for regulators.